
CLAIMS

1. A compound of Formula (I)



(I)

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is phenyl optionally substituted with one or more halo substituents;

R^2 is H or fluoro;

X^1 is CH_2 or O;

R^4 is a mono or bicyclic heteroaryl, optionally substituted with one or more R^3 substituents;

each R^3 is indenpendently selected from C_{6-10}aryl, benzyl, C_{1-6}alkyl, C_{3-7}cycloalkoxy, hydroxyC_{1-6}alkyl, C_{1-6}alkoxyC_{1-6}alkyl, halo, haloC_{1-6}alkyl, OR^5, CN, C(O)OC_{1-6}alkyl, OH, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, 5- to 10 membered heteroaryl, 4-10 membered heterocyclyl, -$C(O)NH_2$, and NR^aR^b, wherein R^a and R^b are independently H, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-6}alkyl or halo C_{1-6}alkyl;

wherein said aryl, heterocyclyl, heteroaryl, C_{3-7}cycloalkyl, C_{3-7}cycloakenyl, C_{3-7}cycloalkoxy are further optionally substituted with one or more substituents independently selected from OH, CN, C_{3-7}cycloalkyl, C3-7cycloalkoxy, NH_2, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy,hydroxyC1-6alkyl, -S-C_{1-6}alkyl; -S-(haloC_{1-6}alkyl), halo , haloC_{1-6}alkyl, -C(O)-C_{1-6}alkyl, phenyl optionally further substituted with halo; and heteroaryl optionally substituted with halo, C_{1-6}alkyl, haloC_{1-6}alkyl or C_{3-7}cycloalkyl;

R^5 is C_{1-6}alkyl, haloC_{1-6}alkyl, hydroxyC_{1-6}alkyl, alkoxyC_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, C_{3-7}cycloalkylC_{1-6}alkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;

wherein phenyl, heterocyclyl and C_{3-7}cycloakyl, C_{3-7}cycloalkylC_{1-6}alkyl, C_{3-7}cycloalkylC_{1-6}akenyl is optionally substituted by one or more substituents selected from C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl optionally further substituted with halo; heterocyclyl optionally further substitued with C_{1-6}alkyl or haloC_{1-6}alkyl;


with the proviso that when R^2 is F, then X^1 is CH_2.

2. The compound according the claim 1, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from the group consisting of pyrimidinyl, pyrazinyl, triazolyl, triazinyl, pyridinyl, pyridine oxide, pyrimidine oxide, pyrazine oxide, quinolinyl, quinazolinyl, quinoxalinyl, indazolyl, pyrazolopyrimidinyl, pyridopyrazinyl, triazolopyridazinyl, benzooxazolyl, oxadiazolyl, tetrazolyl, thiadiazolyl, oxazolyl, and thiazolyl, each of which is optionally substituted with one or more R^3 substituents;

each R^3 is indenpendently selected from C_{6-10}aryl, benzyl, C_{1-6}alkyl, C_{3-7}cycloalkoxy, hydroxyC_{1-6}alkyl, C_{1-6}alkoxyC_{1-6}alkyl, halo, haloC_{1-6}alkyl, OR^5, CN, C(O)OC_{1-6}alkyl, OH, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, 5- to 10 membered heteroaryl, 4-10 membered heterocyclyl, -$C(O)NH_2$, and NR^aR^b, wherein R^a and R^b are independently H, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-6}alkyl or halo C_{1-6}alkyl;

wherein said aryl, heterocyclyl, heteroaryl, C_{3-7}cycloalkyl, C_{3-7}cycloakenyl, C_{3-7}cycloalkoxy are further optionally substituted with one or more substituents independently selected from OH, CN, C_{3-7}cycloalkyl, C3-7cycloalkoxy, NH_2, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy,hydroxyC1-6alkyl, -S-C_{1-6}alkyl; -S-(haloC_{1-6}alkyl), halo , haloC_{1-6}alkyl, -C(O)-C_{1-6}alkyl, phenyl optionally further substituted with halo; and heteroaryl optionally substituted with halo, C_{1-6}alkyl, haloC_{1-6}alkyl or C_{3-7}cycloalkyl; and wherein
R^5 is C_{1-6}alkyl, haloC_{1-6}alkyl, hydroxyC_{1-6}alkyl, alkoxyC_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, C_{3-7}cycloalkylC_{1-6}alkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;
wherein phenyl, heterocyclyl and C_{3-7}cycloakyl, C_{3-7}cycloalkylC_{1-6}alkyl, C_{3-7}cycloalkylC_{1-6}akenyl is optionally substituted by one or more substituents selected from C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl optionally further substituted with halo; heterocyclyl optionally further substitued with C_{1-6}alkyl or haloC_{1-6}alkyl; or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from:



wherein the * depicts the point of attachment to the nitrogen of the spiropiperidinyl moiety; and


wherein n is an integer between 1 and 3; p is 1 or 2, s is an integer between 1 and 4; and R^{3a}, R^{3b} and R^{3c} are independently selected from the group consisting of H, C_{6-10}aryl, benzyl, C_{1-6}alkyl, C_{3-7}cycloalkoxy, hydroxyC_{1-6}alkyl, C_{1-6}alkoxyC_{1-6}alkyl, halo, haloC_{1-6}alkyl, OR^5, CN, C(O)OC_{1-6}alkyl, OH, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, 5- to 10 membered heteroaryl, 4-10 membered heterocyclyl, -C(O)NH_2, and NR^aR^b, wherein R^a and R^b are independently H, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-6}alkyl or halo C_{1-6}alkyl;

wherein said aryl, heterocyclyl, heteroaryl, C_{3-7}cycloalkyl, C_{3-7}cycloakenyl, C_{3-7}cycloalkoxy are further optionally substituted with one or more substituents independently selected from OH, CN, C_{3-7}cycloalkyl, C3-7cycloalkoxy, NH_2, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy,hydroxyC1-6alkyl, -S-C_{1-6}alkyl; -S-(haloC_{1-6}alkyl), halo , haloC_{1-6}alkyl, -C(O)-C_{1-6}alkyl, phenyl optionally further substituted with halo; and heteroaryl optionally substituted with halo, C_{1-6}alkyl, haloC_{1-6}alkyl or C_{3-7}cycloalkyl;

R^5 is C_{1-6}alkyl, haloC_{1-6}alkyl, hydroxyC_{1-6}alkyl, alkoxyC_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, C_{3-7}cycloalkylC_{1-6}alkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;
wherein phenyl, heterocyclyl and C_{3-7}cycloakyl, C_{3-7}cycloalkylC_{1-6}alkyl, C_{3-7}cycloalkylC_{1-6}akenyl is optionally substituted by one or more substituents selected from C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl optionally further substituted with halo; heterocyclyl optionally further substitued with C_{1-6}alkyl or haloC_{1-6}alkyl; and wherein

R^{3d} is selected from H, C_{6-10}aryl, C_{1-6}alkyl, haloC_{1-6}alkyl, C_{3-6}cycloalkyl, 5- or 6-membered heteroaryl; and wherein said aryl, cycloalkyl, heteroaryl are further optionally substituted with one or more substituents independently selected from C_{3-6}cycloalkyl, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, halo and haloC_{1-6}alkyl; or a pharmaceutically acceptable salt thereof.

4. The compound according to any one of claims 1 to 3 wherein the compound has Formula (II); or a pharmaceutically acceptable salt thereof:



(II)

wherein R^{3a}, R^{3b} and R^{3c} are independently selected from the group consisting of H, C_{6-10}aryl, benzyl, C_{1-6}alkyl, C_{3-7}cycloalkoxy, hydroxyC_{1-6}alkyl, C_{1-6}alkoxyC_{1-6}alkyl, halo, haloC_{1-6}alkyl, OR^5, CN, C(O)OC_{1-6}alkyl, OH, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, 5- to 10 membered heteroaryl, 4-10 membered heterocyclyl, -C(O)NH_2, and NR^aR^b, wherein R^a and R^b are independently H, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-6}alkyl or halo C_{1-6}alkyl;


wherein said aryl, heterocyclyl, heteroaryl, C_{3-7}cycloalkyl, C_{3-7}cycloakenyl, C_{3-7}cycloalkoxy are further optionally substituted with one or more substituents independently selected from OH, CN, C_{3-7}cycloalkyl, C3-7cycloalkoxy, NH_2, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy,hydroxyC1-6alkyl, -S-C_{1-6}alkyl; -S-(haloC_{1-6}alkyl), halo , haloC_{1-6}alkyl, -C(O)-C_{1-6}alkyl, phenyl optionally further substituted with halo; and heteroaryl optionally substituted with halo, C_{1-6}alkyl, haloC_{1-6}alkyl or C_{3-7}cycloalkyl;

R^5 is C_{1-6}alkyl, haloC_{1-6}alkyl, hydroxyC_{1-6}alkyl, alkoxyC_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, C_{3-7}cycloalkylC_{1-6}alkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;
wherein phenyl, heterocyclyl and C_{3-7}cycloakyl, C_{3-7}cycloalkylC_{1-6}alkyl, C_{3-7}cycloalkylC_{1-6}akenyl is optionally substituted by one or more substituents selected from C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl optionally further substituted with halo; heterocyclyl optionally further substitued with C_{1-6}alkyl or haloC_{1-6}alkyl; or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein
R^{3a} is H; NH_2 or hydroxyC_{1-3}alkyl;
R^{3b} is selected from the group consisting of halo, C_{1-6}alkyl, haloC_{1-6}alkyl, C_{3-7}cycloalkyl, OR^5, 4-10 membered heterocyclyl, 5- to 10-membered heteroaryl, phenyl, and wherein said heterocyclyl, heteroaryl, phenyl and cycloalkyl is further optionally substituted with one or more substituents independently selected from C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, halo and haloC_{1-6}alkyl; wherein

R^5 is C_{1-6}alkyl, haloC_{1-6}alkyl, C_{3-7}cycloalkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;
wherein phenyl, heterocyclyl or C_{3-7}cycloakyl is optionally substituted by one or more substituents independently selected from C_{1-6}alkyl, haloC_{1-6}alkyl, C_{1-6}alkoxy and halo; and R^{3c} is H or halo.

6. The compound according to any one of claims 1 to 3, wherein the compound has Formula (III); or a pharmaceutically acceptable salt thereof:




(III); wherein

wherein Y^1 is N or CR^{3c}; and wherein R^{3a}, R^{3b} and R^{3c} are independently selected from the group consisting of H, C_{6-10}aryl, benzyl, C_{1-6}alkyl, C_{3-7}cycloalkoxy, hydroxyC_{1-6}alkyl, C_{1-6}alkoxyC_{1-6}alkyl, halo, haloC_{1-6}alkyl, OR^5, CN, C(O)OC_{1-6}alkyl, OH, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, 5- to 10 membered heteroaryl, 4-10 membered heterocyclyl, -C(O)NH_2, and NR^aR^b, wherein R^a and R^b are independently H, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-6}alkyl or halo C_{1-6}alkyl;

wherein said aryl, heterocyclyl, heteroaryl, C_{3-7}cycloalkyl, C_{3-7}cycloakenyl, C_{3-7}cycloalkoxy are further optionally substituted with one or more substituents independently selected from OH, CN, C_{3-7}cycloalkyl, C_{3-7}cycloalkoxy, NH_2, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy,hydroxyC1-6alkyl, -S-C_{1-6}alkyl; -S-(haloC_{1-6}alkyl), halo , haloC_{1-6}alkyl, -C(O)-C_{1-6}alkyl, phenyl optionally further substituted with halo; and heteroaryl optionally substituted with halo, C_{1-6}alkyl, haloC_{1-6}alkyl or C_{3-7}cycloalkyl;

R^5 is C_{1-6}alkyl, haloC_{1-6}alkyl, hydroxyC_{1-6}alkyl, alkoxyC_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, C_{3-7}cycloalkylC_{1-6}alkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;
wherein phenyl, heterocyclyl and C_{3-7}cycloakyl, C_{3-7}cycloalkylC_{1-6}alkyl, C_{3-7}cycloalkylC_{1-6}akenyl is optionally substituted by one or more substituents selected from C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl optionally further substituted with halo; heterocyclyl optionally further substitued with C_{1-6}alkyl or haloC_{1-6}alkyl; or a pharmaceutically acceptable salt thereof.

7. The compound according to any one of claims 1 to 3, wherein the compound has Formula (IV); or a pharmaceutically acceptable salt thereof:



(IV); and wherein

R^1 is as defined in Formula I,

Y^2 is N or CR^{3b}; and wherein


R^{3a}, R^{3b}, R^{3c} and R^{3e} are independently selected from H, C_{6-10}aryl, benzyl, C_{1-6}alkyl, C_{3-7}cycloalkoxy, hydroxyC_{1-6}alkyl, C_{1-6}alkoxyC_{1-6}alkyl, halo, haloC_{1-6}alkyl, OR^5, CN, C(O)OC_{1-6}alkyl, OH, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, 5- to 10 membered heteroaryl, 4-10 membered heterocyclyl, -C(O)NH_2, and NR^aR^b, wherein R^a and R^b are independently H, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-6}alkyl or halo C_{1-6}alkyl;

wherein said aryl, heterocyclyl, heteroaryl, C_{3-7}cycloalkyl, C_{3-7}cycloakenyl, C_{3-7}cycloalkoxy are further optionally substituted with one or more substituents independently selected from OH, CN, C_{3-7}cycloalkyl, C_{3-7}cycloalkoxy, NH_2, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy,hydroxyC1-6alkyl, -S-C_{1-6}alkyl; -S-(haloC_{1-6}alkyl), halo , haloC_{1-6}alkyl, -C(O)-C_{1-6}alkyl, phenyl optionally further substituted with halo; and heteroaryl optionally substituted with halo, C_{1-6}alkyl, haloC_{1-6}alkyl or C_{3-7}cycloalkyl;

R^5 is C_{1-6}alkyl, haloC_{1-6}alkyl, hydroxyC_{1-6}alkyl, alkoxyC_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, C_{3-7}cycloalkylC_{1-6}alkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;

wherein phenyl, heterocyclyl and C_{3-7}cycloakyl, C_{3-7}cycloalkylC_{1-6}alkyl, C_{3-7}cycloalkylC_{1-6}akenyl is optionally substituted by one or more substituents selected from C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl optionally further substituted with halo; heterocyclyl optionally further substitued with C_{1-6}alkyl or haloC_{1-6}alkyl; or a pharmaceutically acceptable salt thereof.

8. The compound according to any one of claims 1 to 3, wherein the compound has Formula (V); or a pharmaceutically acceptable salt thereof:



(V); wherein

Y^3 is N, NR^{3d} or CR^{3a};

Y^4 is N, NR^{3f} or CR^{3b};

Y^5 is N, NR^{3g} or CR^{3c};

Y^6 is N, NR^{3h} or CR^{3e};

wherein R^{3a}, R^{3b}, R^{3c}, R^{3e} are independently selected from H, C_{6-10}aryl, benzyl, C_{1-6}alkyl, C_{3-7}cycloalkoxy, hydroxyC_{1-6}alkyl, C_{1-6}alkoxyC_{1-6}alkyl, halo, haloC_{1-6}alkyl, OR^5, CN, C(O)OC_{1-6}alkyl, OH, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, 5- to 10 membered heteroaryl, 4-10 membered heterocyclyl, -C(O)NH_2, and NR^aR^b, wherein R^a and R^b are independently H, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-6}alkyl or halo C_{1-6}alkyl;

wherein said aryl, heterocyclyl, heteroaryl, C_{3-7}cycloalkyl, C_{3-7}cycloakenyl, C_{3-7}cycloalkoxy are further optionally substituted with one or more substituents independently selected from OH, CN, C_{3-7}cycloalkyl, C3-7cycloalkoxy, NH_2, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy,hydroxyC1-6alkyl, -S-C_{1-6}alkyl; -S-(haloC_{1-6}alkyl), halo , haloC_{1-6}alkyl, -C(O)-C_{1-6}alkyl, phenyl optionally further substituted with halo; and heteroaryl optionally substituted with halo, C_{1-6}alkyl, haloC_{1-6}alkyl or C_{3-7}cycloalkyl;


R^5 is C_{1-6}alkyl, haloC_{1-6}alkyl, hydroxyC_{1-6}alkyl, alkoxyC_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, C_{3-7}cycloalkylC_{1-6}alkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;


wherein phenyl, heterocyclyl and C_{3-7}cycloakyl, C_{3-7}cycloalkylC_{1-6}alkyl, C_{3-7}cycloalkylC_{1-6}akenyl is optionally substituted by one or more substituents selected from C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl optionally further substituted with halo; heterocyclyl optionally further substituted with C_{1-6}alkyl or haloC_{1-6}alkyl;

wherein R^{3d}, R^{3f}, R^{3g}, R^{3h} are independently selected from H, C_{6-10}aryl, C_{1-6}alkyl, haloC_{1-6}alkyl, C_{3-6}cycloalkyl, 5- or 6-membered heteroaryl;

and wherein said aryl, heteroaryl, C_{3-6}cycloalkyl are further optionally substituted with one or more substituents independently selected from C_{3-6}cycloalkyl, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, halo and haloC_{1-6}alkyl; or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 8, or a pharmaceutically acceptable salt thereof,

wherein the moiety:  is selected from the following:



wherein R^{3a}, R^{3b}, R^{3c}, R^{4e} and R^{4f} are as defined in claim 8 and wherein * depicts the point of attachment to the nitrogen of the spiropiperidinyl moiety.

10. The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^1 is phenyl optionally substituted with one or two substitutents independently selected from F and Cl.

11. The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein X^1 is CH_2 and R^2 is F or H.

12. The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein X^1 is O and R^2 is H.

13. The compound according to claim 1, wherein the compound is selected from:
1-(4-chloro-3-fluorophenyl)-9-(1-(4-fluorophenyl)-1H-1,2,4-triazol-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(6-(trifluoromethyl)benzo[d]oxazol-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-5-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(6-(2,2-difluoroethoxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(5-fluoro-6-(pyrrolidin-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(5-fluoro-6-(3-(trifluoromethyl)azetidin-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(4-(pyrrolidin-1-yl)-1,3,5-triazin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(4-(2,2,2-trifluoroethoxy)pyridin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;
2-(1-(4-chloro-3-fluorophenyl)-2-oxo-1,9-diazaspiro[5.5]undecan-9-yl)-4-(4-fluorophenyl)pyridine 1-oxide;
9-(2-(5-azaspiro[2.3]hexan-5-yl)pyrimidin-4-yl)-1-(4-chloro-3-fluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(4-(5-azaspiro[2.3]hexan-5-yl)pyrimidin-2-yl)-1-(4-chloro-3-fluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(2-(3,3-dimethylazetidin-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(5-((1R,2R/1S,2S)-2-(trifluoromethyl)cyclopropyl)-1,2,4-oxadiazol-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(5-(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)-1,2,4-oxadiazol-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(6-hydroxy-3-(pyrrolidin-1-yl)-1,2,4-triazin-5-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(6-(4-fluorophenyl)-4-methyl-3-oxo-3,4-dihydropyrazin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(5-cyclopentyl-1,2,4-triazin-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chlorophenyl)-9-(6-(4-fluorophenyl)pyridin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one
1-(4-chloro-3-fluorophenyl)-9-(4-(trifluoromethyl)pyrimidin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(7-(trifluoromethyl)quinazolin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(5-(4-fluorophenyl)oxazol-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(2-phenyl-2H-tetrazol-5-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(5-(3,3-difluoropyrrolidin-1-yl)-1,2,4-thiadiazol-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(3-(4-fluorophenyl)-1H-1,2,4-triazol-5-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(5-cyclohexyloxazol-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(5-(3-(trifluoromethyl)azetidin-1-yl)-1,2,4-thiadiazol-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(5-(pyrrolidin-1-yl)-1,2,4-thiadiazol-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(5-phenyl-1,3,4-oxadiazol-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(2-(4-fluorophenyl)-2H-1,2,3-triazol-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chlorophenyl)-9-(6-(4-fluorophenyl)pyridin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;
2-(1-(4-chloro-3-fluorophenyl)-2-oxo-1,9-diazaspiro[5.5]undecan-9-yl)-4-(4-fluorophenyl)pyridine 1-oxide;
4-(3-chlorophenoxy)-2-(1-(3,4-difluorophenyl)-2-oxo-1,9-diazaspiro[5.5]undecan-9-yl)pyridine 1-oxide;
9-(2-(5-azaspiro[2.3]hexan-5-yl)pyrimidin-4-yl)-1-(4-chloro-3-fluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(4-(5-azaspiro[2.3]hexan-5-yl)pyrimidin-2-yl)-1-(4-chloro-3-fluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(5-fluoro-6-(pyrrolidin-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(5-fluoro-6-(3-(trifluoromethyl)azetidin-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(4-(pyrrolidin-1-yl)-1,3,5-triazin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(4-(4-amino-4-(trifluoromethyl)piperidin-1-yl)pyrimidin-2-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(4-(4-hydroxy-4-(trifluoromethyl)piperidin-1-yl)-1,3,5-triazin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-5-fluoro-6-(4-hydroxy-4-(trifluoromethyl)piperidin-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(6-(4-hydroxy-4-(trifluoromethyl)piperidin-1-yl)pyridazin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(6-amino-2-(3-hydroxy-3-methylazetidin-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(6-(3,3,4,4-tetrafluoropyrrolidin-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(6-(1,4-oxazepan-4-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
rac-9-(2-amino-6-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(2-methyl-6-(1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
4-(1-(3,4-difluorophenyl)-2-oxo-1,9-diazaspiro[5.5]undecan-9-yl)-6-(1H-pyrazol-1-yl)pyrimidine-2-carbonitrile;
1-(3,4-difluorophenyl)-9-(2-methoxy-6-(1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(6-(1H-pyrazol-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(2-morpholino-6-(1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(2-(dimethylamino)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(6-(1H-1,2,4-triazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(6-(4-chloro-1H-pyrazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(6-(4-fluoro-1H-pyrazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(6-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(6-(4-(trifluoromethyl)-1H-imidazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-5-fluoro-6-(1H-pyrazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(4-amino-6-(4-fluoro-1H-pyrazol-1-yl)-1,3,5-triazin-2-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(6-(oxetan-3-yloxy)-2-(trifluoromethyl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(6-(oxazol-2-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(6-amino-2-(pyridin-2-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(4-(trifluoromethyl)-1*H*-pyrazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecane-2-one;
1-(3,4-difluorophenyl)-9-(2-(2-hydroxypropan-2-yl)-6-(4-(trifluoromethyl)- 1H-pyrazol-1-yl)pyrimidin-4-yl)1,9-diazaspiro[5.5]undecane-2-one;
Synthesis 1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)1,9-diazaspiro[5.5]undecane-2-one;
rac-1-(3,4-difluorophenyl)-9-(2-(1-hydroxymethyl)-6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)1,9-diazaspiro[5.5]undecane-2-one;
4-(1-(3,4-difluorophenyl)-2-oxo-1,9-diazaspiro[5.5]undecane-9-yl-6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-2-carboxamide;
9-(2-chloro-6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
(R)-9-(2-chloro-6-((tetrahydrofuran-3-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
(S)-9-(2-chloro-6-((tetrahydrofuran-3-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
(R)-9-(4-chloro-6-((tetrahydrofuran-3-yl)oxy)pyrimidin-2-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(6-(4-fluoro-1H-pyrazol-1-yl)-2-morpholinopyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(4,4-difluorocyclohex-1-en-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(4-fluorophenyl-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecane-2-one;
9-(2-amino-6-(trifluoromethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(perfluoroethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecane-2-one;

9-(2-amino-6-(1,1,2,2-tetrafluoroethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(2-(hydroxynethyl)-6-(perfluoroethyl)pyrimidin-4-yl)- 1,9-diazaspiro[5.5]undecane-2-one;
1-(3,4-difluorophenyl)-9-(2-(2-hydroxypropan-2-yl)-6-(trifluoromethyl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(4-(2,2,2-trifluoroethoxy)pyridin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(4-chloro-3-fluorophenyl)-9-(6-(2,2-difluoroethoxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(4-propoxypyrimidin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;
rac-1-(3,4-difluorophenyl)-9-(6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-chloro-6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
(S)-9-(2-amino-6-(2,2,2-trifluoro-1-(oxetan-3-yl)ethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
(R)-9-(2-amino-6-(2,2,2-trifluoro-1-(oxetan-3-yl)ethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
(R)-9-(2-amino-6-(2,2,2-trifluoro-1-(oxetan-3-yl)ethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
(S)-9-(2-amino-6-(2,2,2-trifluoro-1-(oxetan-3-yl)ethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(3,3-difluorocyclobutoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(2,2,2-trifluoroethoxy-1,1-d2)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-isopropoxypyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(2-hydroxyethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

rac-9-(2-amino-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
rac-9-(2-amino-6-(2,2,2-trifluoro-1-(3-methyloxetan-3-yl)ethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(2,2,3,3,3-pentafluoropropoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
rac-9-(2-amino-6-((4,4-difluorotetrahydrofuran-3-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
rac-9-(2-amino-6-(((3S,4S)-3-fluorotetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
(R)-9-(2-amino-6-((tetrahydro-2H-pyran-3-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
rac-9-(2-amino-6-(((3R,4R)-4-fluorotetrahydrofuran-3-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-((tetrahydro-2H-pyran-4-yl-4-d)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
rac-9-(2-amino-6-((3-methyltetrahydrofuran-3-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
r*ac*-9-(2-amino-6-(((3S,4R)-4-fluorotetrahydrofuran-3-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
rac-1-(3,4-difluorophenyl)-9-(6-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)oxy)-2-(hydroxymethyl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
rac-1-(3,4-difluorophenyl)-9-(6-(((3R,4R)-4-fluorotetrahydrofuran-3-yl)oxy)-2-(hydroxymethyl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
(S)-1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-((tetrahydrofuran-3-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
(S)-1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
(R)-1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
(R)-1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

(S)-1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
rac ethyl 4-(1-(3,4-difluorophenyl)-2-oxo-1,9-diazaspiro[5.5]undecane-9-yl)-6-(((3S,4S)-4-fluorotetrahydrofuran-3-yl)oxy)pyrimidine-2-carboxylate;
(R)-9-(2-amino-6-((tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;
(R)-9-(2-amino-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one;
(S)-9-(2-amino-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one;
(S)-9-(2-amino-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one;
(R)-9-(2-amino-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one;
1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one;
(*R*)-9-(2-amino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-4-fluoro-1,9-diazaspiro[5.5]undecan-2-one;
(*S*)-9-(2-amino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-4-fluoro-1,9-diazaspiro[5.5]undecan-2-one;
(*S*)-9-(2-amino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-4-fluoro-1,9-diazaspiro[5.5]undecan-2-one;
(*R*)-9-(2-amino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-4-fluoro-1,9-diazaspiro[5.5]undecan-2-one;
rac-9-(2-amino-6-(perfluoroethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-4-fluoro-1,9-diazaspiro[5.5]undecan-2-one;
rac-1-(3,4-difluorophenyl)-4-fluoro-9-(6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(1,1-difluoroethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one; and
1-(3,4-difluorophenyl)-4-fluoro-9-(6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one; or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
1-(3,4-difluorophenyl)-9-(6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-6-(4-(trifluoromethyl)-1*H*-pyrazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecane-2-one;
(R)-9-(2-amino-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one,
(S)-9-(2-amino-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(1,1-difluoroethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one; and
9-(2-amino-6-(trifluoromethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one.

15. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 14 and one or more pharmaceutically acceptable carriers.

16. A combination comprising a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, and one or more therapeutic agents.

17. A combination according to claim 16 wherein one or more therapeutic agents are independently selected from steroid; corticosteroids; glucocorticosteroids; non-steroidal glucocorticoid receptor agonists; leukotriene receptor antagonists (LTRAs) including LTB4 antagonists, LTD4 antagonists, Leukotriene A4 hydrolase (LTA4H) inhibitors, Cysteinyl-Leukotriene Receptor antagonists (including Montelukast, Pranlukast, Zafirlukast); a modulator of prostaglandin pathway (e.g. CRTH2/DP2 receptor antagonist); Bruton's tyrosine Kinase inhibitors (BTK inhibitors); PDE4 inhibitors; antihistamines; histamine H4 receptor antagonist; H1 receptor antagonists; beta-adrenergic drugs such as beta (β)-2-adrenoceptor agonists; anticholinergic drugs or and anticholinergic or antimuscarinic agents (e.g. M2 and/or M3 antagonists); nonsteroidal anti-inflammatory drugs ("NSAIDs"); analgesics; inhibitors of 5-lipoxygenase; inhibitors of FLAP (5- lipoxygenase activting protein); COX-2 selective inhibitors and statins.

18. A combination according to claim 16 comprising a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, and a leukotriene A4 hydrolase inhibitor selected from the group consisting of (*S*)-3-amino-4-(5-(4-((5-chloro-3-fluoropyridin-2-yl)oxy)phenyl)-2*H*-tetrazol-2-yl)butanoic acid; (*S*)-3-amino-4-(5-(4-(4-chlorophenoxy)-phenyl)-2*H*-tetrazol-2-yl)butanoic acid; (*R*)-3-amino-4-(5-(3-phenethoxyphenyl)-2*H*-tetrazol-2-yl)butanoic acid; (*S*)-3-amino-4-(5-(4-(*p*-tolyloxy)phenyl)-2*H*-tetrazol-2-yl)butanoic acid; (*R*)-3-amino-4-(5-(4-butoxyphenyl)-2*H*-tetrazol-2-yl)butanoic acid; acid; (*R*)-3-amino-4-(5-(4-phenethoxyphenyl)-2*H*-tetrazol-2-yl)butanoic acid; and (*R*)-3-amino-4-(5-(4-(4-chlorophenoxy)-phenyl)-2*H*-tetrazol-2-yl)butanoic acid; or pharmaceutically acceptable salt thereof.

~~19. A method of modulating LTC4S activity in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.~~


~~20. A method of treating a disorder selected from allergic disorders, asthma, childhood wheezing, chronic obstructive pulmonary disease, aspirin exacerbated respiratory disease, bronchopulmonary dysplasia, cystic fibrosis, interstitial lung disease (e.g. sarcoidosis, pulmonary fibrosis, scleroderma lung disease, and usual interstitial in pneumonia), ear nose and throat diseases (e.g. sinusitis, rhinitis, nasal polyposis, rhinosinusitis, otitis media, and allergic eosinophilic esophagitis), eye diseases (e.g. conjunctivitis and giant papillary conjunctivitis), skin diseases (e.g. psoriasis, atopic dermatitis, eczema and chronic urticaria), rheumatic diseases (e.g. rheumatoid arthritis, arthrosis, psoriasis arthritis, osteoarthritis, systemic lupus erythematosus, systemic sclerosis), vasculitis (e.g. Henoch-Schonlein purpura, Loffler's syndrome and Kawasaki disease), cardiovascular diseases (e.g. atherosclerosis, cerebrovascular diseases, acute ischemic heart attacks and post-heart attack treatment), gastrointestinal diseases (e.g. eosinophilic diseases in the gastrointestinal system, inflammatory bowel disease, irritable bowel syndrome, colitis, celiaci and gastric haemorrhagia), urologic diseases (e.g. glomerulonephritis, interstitial cystitis, nephritis, nephropathy, nephrotic syndrome, hepatorenal syndrome, and nephrotoxicity), diseases of the central nervous system (e.g. cerebral ischemia, spinal cord injury, migraine, multiple sclerosis, and sleep-disordered breathing), endocrine diseases (e.g. autoimmune thyreoiditis, diabetes-related inflammation), urticaria, anaphylaxis, angioedema, oedema in Kwashiorkor, dysmenorrhoea, burn-induced oxidative injury, multiple trauma, pain (inflammatory and neuropathic), endotoxin shock, sepsis, bacterial infections (e.g. from Helicobacter pylori, Pseudomonas aerugiosa or Shigella dysenteriae), fungal infections (e.g.~~

~~vulvovaginal candidasis), viral infections (e.g. hepatitis, meningitis, parainfluenza and respiratory syncytial virus), hypereosinofilic syndrome, and malignancies (e.g. Hodgkin's lymphoma, leukemia (e.g. eosinophil leukemia and chronic myelogenous leukemia), mastocytos, polycytemi vera, and ovarian carcinoma) wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.~~

~~21~~19. A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, for use as a medicament, in particular for inhibiting LTC4S activity.

~~22~~20. Use of the~~A~~ compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, ~~for use~~ in the manufacture of a medicament for ~~in~~ the treatment of a disorder selected from allergic disorders, asthma, childhood wheezing, chronic obstructive pulmonary disease, aspirin exacerbated respiratory disease, bronchopulmonary dysplasia, cystic fibrosis, interstitial lung disease (e.g. sarcoidosis, pulmonary fibrosis, scleroderma lung disease, and usual interstitial in pneumonia), ear nose and throat diseases (e.g. sinusitis, rhinitis, nasal polyposis, rhinosinusitis, otitis media, and allergic eosinophilic esophagitis), eye diseases (e.g. conjunctivitis and giant papillary conjunctivitis), skin diseases (e.g. psoriasis, atopic dermatitis, eczema and chronic urticaria), rheumatic diseases (e.g. rheumatoid arthritis, arthrosis, psoriasis arthritis, osteoarthritis, systemic lupus erythematosus, systemic sclerosis), vasculitis (e.g. Henoch-Schonlein purpura, Loffler's syndrome and Kawasaki disease), cardiovascular diseases (e.g. atherosclerosis, cerebrovascular diseases, acute ischemic heart attacks and post-heart attack treatment), gastrointestinal diseases (e.g. eosinophilic diseases in the gastrointestinal system, inflammatory bowel disease, irritable bowel syndrome, colitis, celiaci and gastric haemorrhagia), urologic diseases (e.g. glomerulonephritis, interstitial cystitis, nephritis, nephropathy, nephrotic syndrome, hepatorenal syndrome, and nephrotoxicity), diseases of the central nervous system (e.g. cerebral ischemia, spinal cord injury, migraine, multiple sclerosis, and sleep-disordered breathing), endocrine diseases (e.g. autoimmune thyreoiditis, diabetes-related inflammation), urticaria, anaphylaxis, angioedema, oedema in Kwashiorkor, dysmenorrhoea, burn-induced oxidative injury, multiple trauma, pain (inflammatory and neuropathic), endotoxin shock, sepsis, bacterial infections (e.g. from Helicobacter pylori, Pseudomonas aerugiosa or Shigella dysenteriae), fungal infections (e.g. vulvovaginal candidasis), viral infections (e.g. hepatitis, meningitis, parainfluenza and respiratory syncytial virus), hypereosinofilic syndrome, and malignancies (e.g. Hodgkin's lymphoma, leukemia (e.g. eosinophil leukemia and chronic myelogenous leukemia), mastocytos, polycytemi vera, and ovarian carcinoma).





~~23~~21. A compound of selected from the group consisting of:







,






,

,

,


,

,

;

;


,

,

,

,

,


,

,

,

,


wherein PG is a nitrogen protecting group; and PG^2 is a carboxylic acid protecting group; PG^3 is carbobenzyloxy (Cbz) or *tert*-butoxycarbonyl (BOC); each R^{1a} is halo, each R^{1b} is independently selected from F and Cl; v is 1-3, and R^1 is phenyl optionally substituted with one, two or three halo substituents.